NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Sees Significant Decrease in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) was the recipient of a large drop in short interest in May. As of May 15th, there was short interest totaling 5,154 shares, a drop of 83.1% from the April 30th total of 30,482 shares. Based on an average trading volume of 45,351 shares, the days-to-cover ratio is currently 0.1 days.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ NRXPW remained flat at $0.00 during midday trading on Friday. 176,260 shares of the stock were exchanged, compared to its average volume of 33,307. NRx Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.18. The stock’s 50-day simple moving average is $0.01 and its 200 day simple moving average is $0.04.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for neuropsychiatric and neurodegenerative disorders. The company’s research pipeline includes small‐molecule candidates designed to address underlying pathophysiological mechanisms implicated in conditions such as Rett syndrome, Alzheimer’s disease and Long COVID. Leveraging a proprietary formulation and delivery approach, NRx seeks to advance compounds that have demonstrated safety in prior studies toward new indications with significant unmet medical need.

Among its lead programs, NRx is developing NP-120 (sarizotan) for the treatment of Rett syndrome, a rare genetic disorder that impacts brain development in young girls.